In Oct 2007, the FDA declared that the labeling for all PDE5 inhibitors, which includes tadalafil, demands a far more prominent warning of the prospective risk of unexpected hearing loss as the results of post-marketing reports of temporary deafness associated with usage of PDE5 inhibitors.[19]Your World wide web browser is no longer supported by M… Read More